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Background: Endothelin-1 (ET1) is a marker of endothelial dysfunction and is secreted in response to angiotensin II, shear stress, and 
inflammation. C-terminal pro-endothelin-1 (proET) is a precursor to ET1 that is more easily measured. Statins have pleiotropic effects, 
including improving endothelial function and reducing inflammation. There have been no studies to date looking at statin use in acute heart 
failure (AHF) based on proET levels.
methods: This subset analysis of the Biomarkers in Acute Heart Failure trial included 562 patients with AHF who had initial proET levels 
drawn. Patient outcomes were assessed at 90 days. Cox regression analysis was used to evaluate all cause mortality and Kaplan-Meir 
analysis was used to compare survival.
results: Patients with AHF had elevated proET levels (159.9 ± 80.6) compared to those without AHF (86.5 ± 63.4, p < 0.001). The median 
proET level (145.2 [102.7,194.5]) was used to stratify patients. Multivariate cox regression analysis for mortality included covariates NT-
proBNP levels and history of stroke. Subjects with AHF and elevated proET levels discharged on a statin had a hazards ratio of 0.50 ([0.30, 
0.83], p = 0.007). Those with elevated proET levels who were discharged on a statin had decreased mortality at 90 days (p = 0.044) based 
on Kaplan-Meir analysis.
conclusion:  Patients who had elevated proET levels had decreased mortality if discharged on a statin. Further studies assessing this 
biomarker as a target for therapy with statins should be considered. 
